BD Acquires Edwards Lifesciences’ Critical Care Business for $4.2 Billion

BD (Becton, Dickinson and Company) and Edwards Lifesciences have announced a definitive agreement under which BD will acquire Edwards’ Critical Care product group for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD’s portfolio of smart connected care solutions.

Critical Care is a high-growth, innovative industry leader in advanced patient monitoring with advanced AI algorithms serving millions of patients globally, with approximately 4,500 employees mostly in Irvine, California, and generating $900 million revenue in 2023. Edwards will use the after-tax cash proceeds to fund strategic growth investments, enhancing its balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure. Edwards’ goal is to build the most comprehensive structural heart disease portfolio through its pursuit of breakthrough technologies, indication expansions and world-class evidence for its surgical, TAVR and transcatheter mitral and tricuspid innovations, with the focus on helping even more patients around the world.

“Critical Care expands BD’s portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline that complement BD’s existing technologies serving operating rooms and intensive care units,” said Tom Polen, chairman, chief executive officer and president of BD. “We believe the combination unlocks multiple new avenues for growth and value creation through BD’s broad global footprint, increased penetration across new and existing hospital customers, new innovation opportunities across data sets and platforms, and application of the BD Excellence operating system.”


en_GBEnglish (UK)